1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma

  • August 2015
  • 115 pages
  • GBI Research
Report ID: 3288007

Summary

Table of Contents

Search Inside

Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma

Summary

Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission. Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of ~50%. Re-treatment with chemotherapy can induce second and subsequent remissions, but most NHL patients develop chemotherapy resistant disease, for whom there are limited treatment options. Overall, in terms of numbers small molecule chemotherapeutic agents dominate the current market, with a clear need for novel targeted therapies to prolong durations of remission, and provide options for patients with chemo resistant, heavily pretreated disease.

The current developmental pipeline addresses these gaps in the market, dominated by cancer immunotherapies and inhibitors of cancer-associated signal transduction. Pathways of significant interest include B-cell receptor signaling, the PI3K/Akt/mTOR pathway, and Wnt/ß-catenin signaling, as well as oncogenes such as BCL-6 and BCL-2. Characteristic cell surface molecules that represent targets for cancer immunotherapies include CD19, LMP-1/2 and CD20, with several pipeline drugs already approved for CD20. First-in-class drug development in NHL corresponds strongly to these known somatic mutations and affected pathways. Clinical results of drugs against profiled targets in this report show many are being investigated in relapsed disease.

Scope

There are 666 marketed products for NHL, 95% of which are small molecules -
- What are the dominant mechanisms of action across marketed products?
The treatment of lymphoma is dominated by the use of combination cyclophosphamide based chemotherapy in combination with rituximab -
- What are these chemotherapy regimens?
- How did they perform in key clinical trials?
The variation in molecule type has shifted away from small molecules, whose dominance has decreased to 46% across the pipeline -
- What are the dynamics of the remaining 54% of the pipeline?
- How does this reflect the need for novel targeted therapies?
There is a significant shift away from cytotoxic agents, with the current pipeline dominated by cancer immunotherapies and signal transduction inhibitors -
- What is the scientific rationale behind these mechanisms of action?
- How successful have approved targeted therapies been?
Profiled first-in-class therapies include: PIK3CA, EZH2, CD40 and MDM2 -
- What is the scientific rationale behind these targets?
- What preclinical and clinical results are available for drugs against these targets?
- What is the overall opinion on these targets for drug development across NHL?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the NHL market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the NHL pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in focussed on the development of targeted therapies for this disease.
- Visualize the clinical safety and efficacy of drugs against first-in-class targets via a detailed heat map, outlining the results across major clinical trial endpoints.
- Identify commercial opportunities in the NHL deals landscape by analyzing trends in licensing and co-development deals, and those first-in-class drugs which are yet to be involved in a strategic alliance.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027

Epiomic Epidemiology Series: Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Non-Hodgkin Lymphoma in 18 Major Markets Non-Hodgkin Lymphomas (NHL) are a diverse group of blood cancers that develop from lymphocytes ...

Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast -2023-7MM

Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast -2023-7MM

  • $ 4950
  • Industry report
  • April 2017
  • by Delve Insight

DelveInsight’s “Non-Hodgkin Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023-7MM” Reports provides an overview of the disease and global market size of the Non-Hodgkin Lymphoma ...

Opportunity in Non-Hodgkin Lymphoma Therapeutics in global market - 2017

Opportunity in Non-Hodgkin Lymphoma Therapeutics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.